The Three Liquidity Pressures Unique to Oncology

Cash management at an oncology platform looks different from anywhere else in healthcare. The CFO is dealing with three structural pressures at once: chemo authorization holds that delay revenue, 270-day remit cycles on the longest claims, and acquisition cash sitting in escrow waiting for the next close. None of those exist at the same scale in a typical multispecialty group.

This article lays out the cash management policy a multistate oncology platform actually needs, and the architecture that makes it work.

Why Oncology Cash Cycles Run Long

Three reasons claims revenue takes longer to land in oncology than in almost any other specialty.

First, prior authorization volume. Almost every chemo, immunotherapy, and radiation regimen requires PA. Each PA holds revenue from being billed until approval comes through. On complex cases, that's 30 to 90 days.

Second, claim complexity. Oncology claims involve multiple service lines per encounter, multiple drugs, multiple administration codes, and frequent payer downcoding. Each downcoded line means a resubmission, which means another 30 to 60 days.

Third, secondary payer cycles. Oncology patients often have Medicare plus a secondary plan. After Medicare pays, the secondary claim goes out, which adds another 60 to 90 days. Total cycle time on a complex case can reach 270 days.

The Reserve Sizing Problem

Most healthcare CFOs size their working capital reserve as a function of monthly operating expense. Oncology platforms cannot do that.

The reserve has to cover the gap between billed-but-unpaid AR and outgoing expenses. At an oncology platform with 90-day average MSO and 30-day operating expense burn, the gap is roughly three months of operating cost. For a platform with $50M of annual operating expense, that's $12-15M of reserve, minimum.

If your reserve is sized based on monthly expense, you will run into liquidity stress every quarter. If it's sized based on MSO-adjusted AR cycle, you absorb the variability without scrambling.

Acquisition Cash Sits Separately

PE-backed oncology platforms typically have a separate M&A war chest funded by the sponsor. Mixing that cash into operating accounts creates audit and governance problems. Separate it explicitly.

The architecture: one operating reserve sized to cover the AR cycle gap, one acquisition escrow account holding committed M&A capital, and one yield-bearing sweep target where excess from either bucket parks at 1.75% APY when not deployed. Each bucket has its own signer matrix and approval thresholds.

This separation matters at audit, but it matters more at decision time. Your CFO can answer "do we have the cash to close this deal" without doing math against operating reserves that should not be deployed.

The Authorization Holds Problem

A chemo PA hold ties up revenue in a way that does not show up on most cash forecasts. The encounter is billable but not billed. The service has been provided. The cash exists nowhere in the financial model.

Fix this by tagging authorization-held encounters in your revenue cycle layer and exposing the aggregate in your 13-week forecast. "Billed but pending payer auth approval" should be a distinct AR bucket, not buried in standard AR. The treasury team should be able to see, on demand, how much expected revenue is sitting in authorization holds and roughly when each tranche is expected to clear.

Drug Inventory Financing

The cost-side problem at oncology platforms: chemotherapy drugs are expensive, and most platforms hold weeks of inventory. Some of that inventory ties to specific patient regimens. Some sits as buffer. Either way, drug inventory is working capital that does not earn yield.

Some platforms negotiate consigned inventory with drug wholesalers, which means you only pay when the drug is administered. Others run inventory financing through their bank, where the bank provides a credit line secured by the drug inventory. Both approaches free up cash that would otherwise sit in product.

Your bank should be a partner on inventory financing if your operating cash is consistently constrained by drug costs. If it is not, you are using the wrong bank for this part of your balance sheet.

What Your CFO Should See on Monday Morning

Six numbers, in one dashboard.

• Total operating cash and reserve balance

• Acquisition escrow balance

• Yield-bearing sweep balance and current APY

• AR aging by payer, with PA-held encounters broken out

• 13-week cash forecast with state Medicaid contributions modeled per-cadence

• Drug inventory tied-up capital (purchased but not administered)

Each of those should be one query, not one spreadsheet. If any of them require an export to Excel to answer, your banking and treasury infrastructure is doing something other than its job.

The Policy in One Page

For a multistate oncology platform, the cash management policy should fit on one page and cover:

Reserve sizing (3 months of AR cycle, minimum). Acquisition escrow separation. Yield target on excess (1.75% APY minimum, with FDIC coverage to $10M per entity via IntraFi sweep). Authorization hold tracking as a distinct AR bucket. Drug inventory financing approach. Sweep policies (automated, threshold-based). Signer matrix (by amount and account). Review cadence (weekly cash committee, monthly treasury report to the board).

If your policy currently lives in someone's head and gets reconstructed each board meeting, write it down. Then run it.